Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

Importance of Dose Adjustments of Avatrombopag to Maintain Efficacy …

Weill Cornell Medicine Oncology & Hematology

W. Oncology & Hematology

Defining High-Risk HR+/HER2- eBC: Clinical Pearls for Oncologists

Weill Cornell Medicine Oncology & Hematology

E. Nicolò

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

Inflammatory Breast Cancer - Diagnosis and Management Updates

Weill Cornell Medicine Oncology & Hematology

M. Cristofanilli

ASCO® GI 2024 Insights: "The NEST-1 Trial - Neoadjuvant BOT/BAL in R…

Weill Cornell Medicine Oncology & Hematology

P. Kasi

Year in Review: ctDNA in Colorectal Cancer

Weill Cornell Medicine Oncology & Hematology

P. Kasi

ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in Older …

Insights from 2023 ASH Annual Meeting

S. Rutherford

Monitoring Response to Therapy in mCRPC: What Parameters to Look at

Weill Cornell Medicine Oncology & Hematology

D. Nanus

Radiation Combined With IO for the Treatment of SCLC

Weill Cornell Medicine Oncology & Hematology

A. Saxena

ASCO® 2023 Insights: "Phase I Dose-Escalation Results of PSMA-TRT Wi…

Insights from 2023 ASCO® Annual Meeting

S. Tagawa

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzumab Go…

Insights from 2023 ASCO® Annual Meeting

S. Tagawa

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare Treat…

Insights from 2023 ASCO® Annual Meeting

S. Tagawa

Eltrombopag in ITP: Learnings From the RAISE and EXTEND Trials

Weill Cornell Medicine Oncology & Hematology

J. Bussel

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Stud…

ASCO GU 2023 Conference Coverage

S. Tagawa

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and…

ASCO GU 2023 Conference Coverage

S. Tagawa

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cance…

ASCO GU 2023 Conference Coverage

D. Nanus

Aggressive Lymphoma - Nursing and Allied Providers Symposium

Indy Hematology Review

J. Leonard

Aggressive B-Cell and T-Cell Lymphomas: Emerging Therapies

Indy Hematology Review

J. Leonard

CLONEVO: Cell Cycle Inhibition to Target the Evolution of Urothelial…

Weill Cornell Medicine Oncology & Hematology

B. Faltas

Pain Management in Sickle Cell Disease

Weill Cornell Medicine Oncology & Hematology

S. Jain, J. Bussel

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophi…

ASCO 2022 Conference Coverage

J. Bussel, C. Mcguinn

Eltrombopag for the Treatment of Children With Persistent and Chroni…

Weill Cornell Medicine Oncology & Hematology

J. Bussel

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for …

ASCO 2022 Conference Coverage

P. Kasi

SYK Inhibitors for the Treatment of ITP

Weill Cornell Medicine Oncology & Hematology

J. Bussel

Updates in Mantle Cell Lymphoma

i3 Health

J. Leonard

ASCO GU 2022 Highlights on the ADCs in Advanced Urothelial Cancer: C…

ASCO Genitourinary Cancers Symposium

S. Tagawa

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

ASH 2021 Conference Coverage on VuMedi

P. Desai

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

ASH 2021 Conference Coverage on VuMedi

P. Desai

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

ASH 2021 Conference Coverage on VuMedi

P. Desai

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

Richard T. Silver

MPN Stem Cell Fitness and the Link to Clinical Outcomes

2021 International Congress on Myeloproliferative Neoplasms

J. Scandura

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Ris…

2021 International Congress on Myeloproliferative Neoplasms

G. Abu-Zeinah

Pediatric MPNs: An Unfamiliar Topic

2021 International Congress on Myeloproliferative Neoplasms

N. Kucine

WCLC 2021 Data From IMpower010: Characterization of Stage IB-IIIA NS…

Weill Cornell Medicine Oncology & Hematology

N. Altorki

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary An…

ecancer

J. Allan

Evaluating mCRPC Using 177LU-PNT2002 PSMA Therapy After 2L Hormonal …

Weill Cornell Medicine Oncology & Hematology

S. Tagawa

ASCO 2021 Data on PSMA-Targeted Alpha Emitter 225Ac-J591 in Men With…

Weill Cornell Medicine Oncology & Hematology

S. Tagawa

Newly FDA-Approved Sacituzumab Govitecan for Advanced Urothelial Car…

Weill Cornell Medicine Oncology & Hematology

S. Tagawa

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

3rd Annual Hematologic Malignancies Symposium

G. Roboz

Key Symptoms and HRQoL in Chronic ITP: How Much Does ITP Affect QoL?…

Weill Cornell Medicine Oncology & Hematology

J. Bussel

Managing Hodgkin Lymphoma: PET Adapted Strategies, Applying ECHELON-…

2nd SOHO Italian Conference

J. Leonard

How I Treat DLBCL in 2020: Who Shouldn't Get Standard Treatment? Is …

2nd SOHO Italian Conference

.

2020 Update on TPO Agents: How Effective Are They in Chemotherapy-In…

Weill Cornell Medicine Oncology & Hematology

J. Bussel

ITP Receptor Agonists Efficacy Analysis: Romiplostim, Eltrombopag an…

Weill Cornell Medicine Oncology & Hematology

J. Bussel

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding A…

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Guzman

Management of R/R MCL: Ibrutinib and Acalabrutinib Data, Venetoclax …

PeerView Oncology

J. Ruan

Management of R/R MCL: Lenalidomide w/ Rituximab & CAR T Therapy

PeerView Oncology

J. Ruan

Treatment Options for Older and Elderly Patients With AML: How to Us…

Weill Cornell Medicine Oncology & Hematology

P. Desai

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-F…

12th International Congress on Myeloproliferative Neoplasms

R. Silver

Is There a Role of Transplantation for CML in the Era of TKIs?

12th International Congress on Myeloproliferative Neoplasms

K. Van Besien

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP, EP300, HD…

ESO Lymphoma Course

A. Melnick

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

ESO Lymphoma Course

A. Melnick

Novel Treatment Options for AML and Overview of Related Trials - Mov…

UNMC Leukemia Symposium: Focus on Opportunities to Improve Care

G. Roboz

Treatment and New Trials in DLBCL - Modifications to R-CHOP Based on…

Indy Hematology Review

J. Leonard

Brentuximab Vedotin for Previously Untreated Peripheral T-cell Lymph…

Indy Hematology Review

J. Leonard

Axi cell CAR T-cell Therapy for Refractory DLBCL - Overview of ZUMA-…

Indy Hematology Review

J. Leonard